倱æã®æ°æ²»çæ³ïŒãã€ã¯ãRNAãçšããŠç¶²èè¡ç®¡çŽ°èã®ç°åžžå¢æ®ãé»å®³
ããã®çŒçŸæ£ã«å¯Ÿããæ°ããæ²»çæ³ããå šèšåºè©Šéšã§è¯å¥œãªçµæãåºããŸãããããã«é¢ããè«æã¯ãJournal of Clinical Investigationãã«æ²èŒãããŠããŸãã
ã«ãªãã©ã«ãã¢ã®Scripps Research Instituteãšã«ããã®Mount Sinaiç é¢ãããã³ã«ãªãã©ã«ãã¢å€§åŠã®ç 究ããŒã ã¯ãä»åã®çµæã倱æãé²ãæ°æ²»çæ³ããããããããããªããšè©±ããŠããŸãã
ç³å°¿ç æ§ç¶²èç( diabetic retinopathy)ãé»æå€æ§( macular degeneration)ãªã©ã®å€ãã®å€±æã®ã¿ã€ãã¯ãçŒçã®å¥¥ã«ãã網èã®è¡ç®¡ç°åžžåœ¢æã«é¢é£ããŠãããšãç 究å¡ã¯èª¬æããŸãã網èã¯è¡ç®¡ããã³å æåæ§çŽ°è(light-sensing cells)ããæãè»éšçµç¹ã®èãå±€(thin layer of soft tissue )ã§ãã
çŸæ£ç®¡çäºé²ã»ã³ã¿ãŒ( Centers for Disease Control and Prevention)ã«ããã°ãç±³åœã§ã¯50æ³ä»¥äžã®ãã¡160äžäººãé»æå€æ§çãæ£ã£ãŠãããäžçäžã§ã¯18æ³ä»¥äžã®ãã¡530äžäººä»¥äžãç³å°¿ç æ§ç¶²èçãåããŠããããããããã®çŸæ£ã«å¯Ÿããæ²»çæ³ã®ç¢ºçã¯å«ç·ã®èª²é¡ã§ãã
VEGFã¯è¡ç®¡ã®ç°åžžå¢æ®ããããã
éå»10幎éã§å€ãã®è©Šéšã§ã¯ã網èè¡ç®¡ã®ç°åžžãªå¢å€§ãã©ã®ããã«ããŠæ¢ããããã®ããå€æããããã«ãè¡ç®¡å ç®çŽ°èå¢æ®å å(vascular endothelial growth factor ïŒVEGF)ãšåŒã°ããååã«çç®ããŠããŸããã
ç 究è ã®èª¬æã«ãããšãäœãããããªãé žçŽ ãæç¥ãããšãVEGFãèªçºãããŸããçŒã®è¡ç®¡ãé«æ¿åºŠã®VEGFãæç¥ãããšãããå€ãã®èªçºããããããŸãã
ããã«ãè¡ç®¡å¢æ®ãä¿é²ãããVEGFãšä»ã®ååã¯ãè¡ç®¡æ°çã®åã«åºæ¿ãããRasãšåŒã°ããéºäŒåã掻æ§åãããŸãããã®æ å ±ã«åºã¥ããšãVEGFãæ¢ããããšãã§ããã°ã倱æãæ²»çã§ããããšã«ãªããŸãã
ããããTSRIã®ç 究ããŒã ã¯æšå¹Žãæ£åžžãªèŠåãç¶æããäžã§VEGFãéèŠãªåœ¹å²ãæããããšãæããã«ããŸããããã®ãããVEGFãé»å®³ããå Žåã«ã¯ãçŒã®å æåæ§çŽ°èãæ»ãã§ããŸããé床ã®èŠåé害ãããããå¯èœæ§ããããŸãã
ä»åã®çºèŠã«ããã次ã®èª²é¡ã¯ç°åžžãªè¡ç®¡æ°çãé²ãæ¹æ³ãèŠã€ãåºãããšã«ãªããŸããããããŠãUCSDç çåŠéšã® David Cheresh ãã¯microRNA(ãã€ã¯ãRNA)ããã®ã«ã®ãæ¡ã£ãŠããå¯èœæ§ãèŠåºããŸããã
microRNAãè¡ç®¡çŽ°èå¢æ®ãæšçãšãã
ããŠã¹ãçšããŠçè«ãæ€èšŒããçµæãéºäŒå掻æ§å( gene activation )ããã³çºçŸã調ç¯ããããšã§ç¥ãããRNAã®å°çããã€ã¯ãRNAãã¯ãVEGFäœçšçµè·¯ã®äžæµå°ç¹ã§å¿è¡ç®¡åœ¢æ(neovascularization)ãæšçãšããRas掻æ§åãé²ãããã«äœ¿çšã§ããå¯èœæ§ãããããšãããããŸããã
ãã€ã¯ãRNAã¯çŒã®æ£åžžãªè¡ç®¡ç¶æ ãç¶æããªããç°åžžãªè¡ç®¡åœ¢æãé»å®³ã§ãããããããªãã®ã§ãã